Aclaris Therapts (ACRS) Stock Price, Quote & News

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JA...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 324 7933

Website: www.aclaristx.com

Address:

701 Lee Road, Suite 103, Wayne, United States

Bionco Oct. 25 at 11:18 AM

$ACRS Yesterday's trading volume exceeded 1.9 million shares, surpassing both the 10-day and 3-month averages. Short volume accounted for approximately 25% of total trading, which is not unusually high. The recent high is about twice this year's low, and many retail traders likely took profits after a 100% gain from the bottom. I, however, bought heavily near the lows and am holding my full position. I don’t intend to blame short sellers, day traders, or profit-takers for the price falling, as these activities are integral to the market. All enjoy your trades and have a nice weekend!

1 · Reply

OriginalTradeonrumor Oct. 25 at 6:30 AM

$ACRS the reason is the market runs on algos and when not temporarily over influenced by temp surges in buy/sell volume and of short pressure it will align hence for the most part you can predict movement hence my and others who follows techs can well over 50% reliably make predictions

0 · Reply

Bionco Oct. 25 at 12:54 AM

$ACRS shorting volume is not high today. Retail speculators took profit. That is the reason!

0 · Reply

OriginalTradeonrumor Oct. 24 at 6:04 PM

$ACRS price movement as expected !!!

0 · Reply

Bionco Oct. 24 at 3:12 PM

$ACRS The number of shares available for shorting has fallen to 950,000 from 1.7 million in October 22.

0 · Reply

Bionco Oct. 24 at 2:41 PM

$ACRS sadly, Short sellers are in control of the market

0 · Reply

Bionco Oct. 23 at 2:07 PM

$ACRS it's nice we got traction recently!

0 · Reply

OriginalTradeonrumor Oct. 23 at 12:36 PM

$ACRS we did not get what we needed yesterday …so we will go back down till at least 2.15 area if not lower —I’ll start nibbling at 2.18-2.10 and see how /if that holds …below 2.10 I’ll watch it go to 2.00 and nibble there till 1.95….below that I start going all in in the 1.80’s Let’s see what happens!

2 · Reply

Whales22 Oct. 23 at 6:02 AM

$CRNC $ACRS $SLP $LPTH How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI

0 · Reply

ProfessorGamma Oct. 23 at 12:47 AM

$LOBO $RVYL $EH $ACRS How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI

0 · Reply

Aclaris Therapeutics, Inc. - Special Call

Sep 30, 2025, 7:00 AM EDT - 25 days ago

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep 9, 2025, 7:00 AM EDT - 6 weeks ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aug 27, 2025, 8:00 AM EDT - 2 months ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 7, 2025, 6:59 AM EDT - 2 months ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 29, 2025, 4:01 PM EDT - 3 months ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 28, 2025, 8:45 AM EDT - 3 months ago

Aclaris Therapeutics Announces Leadership Transition

Jun 30, 2025, 9:31 AM EDT - 4 months ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 4:01 PM EDT - 4 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 23, 2025, 6:59 AM EDT - 4 months ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

May 28, 2025, 9:20 AM EDT - 5 months ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 9, 2025, 7:00 AM EDT - 6 months ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 8, 2025, 6:50 AM EDT - 6 months ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 7:00 AM EDT - 6 months ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Mar 4, 2025, 7:00 AM EST - 8 months ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Feb 12, 2025, 6:50 AM EST - 9 months ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Jan 30, 2025, 4:01 PM EST - 9 months ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 6, 2025, 4:30 PM EST - 10 months ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 23, 2024, 1:41 PM EST - 10 months ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Nov 26, 2024, 4:30 PM EST - 11 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 3:27 PM EST - 1 year ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 18, 2024, 8:50 AM EST - 1 year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jun 25, 2024, 12:36 PM EDT - 1 year ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 6:30 AM EDT - 1 year ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 7, 2024, 9:44 PM EDT - 1 year ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Feb 27, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Jan 10, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Dec 19, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Provides Corporate Update

Dec 5, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Nov 13, 2023, 7:19 AM EST - 2 years ago

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Nov 13, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Oct 3, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Sep 28, 2023, 7:18 AM EDT - 2 years ago

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Sep 20, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Jul 11, 2023, 7:31 PM EDT - 2 years ago

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Jun 13, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Jun 2, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

May 8, 2023, 11:56 AM EDT - 2 years ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript

May 8, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Bionco Oct. 25 at 11:18 AM

1 · Reply

OriginalTradeonrumor Oct. 25 at 6:30 AM

0 · Reply

Bionco Oct. 25 at 12:54 AM

$ACRS shorting volume is not high today. Retail speculators took profit. That is the reason!

0 · Reply

OriginalTradeonrumor Oct. 24 at 6:04 PM

$ACRS price movement as expected !!!

0 · Reply

Bionco Oct. 24 at 3:12 PM

$ACRS The number of shares available for shorting has fallen to 950,000 from 1.7 million in October 22.

0 · Reply

Bionco Oct. 24 at 2:41 PM

$ACRS sadly, Short sellers are in control of the market

0 · Reply

Bionco Oct. 23 at 2:07 PM

$ACRS it's nice we got traction recently!

0 · Reply

OriginalTradeonrumor Oct. 23 at 12:36 PM

2 · Reply

Whales22 Oct. 23 at 6:02 AM

$CRNC $ACRS $SLP $LPTH How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI

0 · Reply

ProfessorGamma Oct. 23 at 12:47 AM

$LOBO $RVYL $EH $ACRS How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI

0 · Reply

StockDaddy68 Oct. 22 at 9:41 PM

$ACRS Just as I figured. No problem still long and strong

0 · Reply

Bionco Oct. 22 at 3:18 PM

$ACRS 700k shares have been returned so far today

0 · Reply

Bionco Oct. 22 at 1:45 PM

$ACRS WOW! Looking at the volume!

1 · Reply

OriginalTradeonrumor Oct. 22 at 12:31 PM

$ACRS what’s next technically Closing at $2.38 like we did is 100% great BUT today we need close of ≥ $2.40 on strong volume where we then have a shot at $2.55–$2.75 where we cap out ( unless a catalyst comes in) Look at 2.10-2.20 for support. So net net any move from 2.10 -2.40 is “healthy” where we are setting a new base Above 2.40 watch for ~2.75 cap Below 2.10 we go back to 1.85ish bottom and start all over again

1 · Reply

StockDaddy68 Oct. 22 at 11:33 AM

$ACRS This is a great run however I have a dilemma. Will the stock now take a breather back to the support line or keep going. What are your thoughts?

0 · Reply

StockDaddy68 Oct. 22 at 11:05 AM

$ACRS

0 · Reply

StockScanners Oct. 22 at 2:16 AM

$ACRS keep watch if this holds above 2.30

0 · Reply

swingexpert Oct. 22 at 2:12 AM

$ACRS https://finance.yahoo.com/news/makes-aclaris-therapeutics-acrs-strong-160002628.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACqM-Tmf2AHUUQImVHDiA7vvbL2GzvVyoTvc5upSTSGnbpafuKfnKORwDSACL1Qyr26412hTybnvNQ1RqySkWAyZ0GJ-oNI-mZIj63XLYJvZdW06ZKryZIRE2T6hCr5G_PVvizjgccvMUl1hFndbhNsy0AGsivAtJUaToDmYuPOS

0 · Reply

Bionco Oct. 22 at 12:35 AM

$ACRS Today, I noticed for the first time that CINN appeared as a market maker for ACRS and I’m curious to know who CINN actually is. The answer is as follows. CINN is the market maker code for Citadel Securities, one of the largest and most active market-making firms in the U.S. stock market. Here’s a quick breakdown: CINN stands for Citadel Investment Network which is a routing identifier used by brokers and exchanges. Citadel Securities provides liquidity in thousands of U.S. equities and options, meaning it frequently buys and sells shares to keep trading smooth. When you see CINN show up on Level II quotes or in trade data, it typically indicates Citadel’s trading activity—either filling retail orders from brokerages or executing automated market-making strategies. So, if CINN started showing up in ACRS, it likely means Citadel has begun actively making a market or providing liquidity in that stock—possibly due to rising trading volume or volatility.

1 · Reply

Bionco Oct. 21 at 10:53 PM

$ACRS how did these happen?👇

0 · Reply

topstockalerts Oct. 21 at 3:25 PM

$ACRS Stay tuned for more! 🍾

0 · Reply

StockDaddy68 Oct. 21 at 3:20 PM

$ACRS TO THE MOOOOOON!!!!!

0 · Reply

Market Cap	244.83M
Revenue (ttm)	18.72M
Net Income (ttm)	-132.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-705.50%
Debt to Equity Ratio	0.00

Volume	1,911,900
Avg Vol	1,067,864
Day's Range	N/A - N/A
Shares Out	108.33M
Stochastic %K	53%
Beta	0.26
Analysts	Strong Sell
Price Target	$7.86